renal-cell-carcinoma

Documents about renal-cell-carcinoma

• PSMA Therapy and Immunotherapy in Kidney Cancer#184847ClinicalTrials.gov
• Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)#897760ClinicalTrials.gov
• Renal cell carcinoma#153463PMC Full-Text (OAI)
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery#803372ClinicalTrials.gov
• Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney#1033085ClinicalTrials.gov
• Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery#272336ClinicalTrials.gov
• Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma#146447ClinicalTrials.gov
• Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma#868529ClinicalTrials.gov
• Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma#918548ClinicalTrials.gov
• A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma#829337ClinicalTrials.gov
• The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma#858932ClinicalTrials.gov
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma#882751ClinicalTrials.gov
• AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)#885749ClinicalTrials.gov
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma#879988ClinicalTrials.gov
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma#424184ClinicalTrials.gov
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma#869797ClinicalTrials.gov
• Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.#852126ClinicalTrials.gov
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial#140997ClinicalTrials.gov
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma#216976ClinicalTrials.gov
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial#180375ClinicalTrials.gov
• Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy#162487ClinicalTrials.gov
• Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma#850088ClinicalTrials.gov
• Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program#889508ClinicalTrials.gov
• [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma#908533ClinicalTrials.gov
• 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma#1031880ClinicalTrials.gov
• Renal Adjuvant MultiPle Arm Randomised Trial#252984ClinicalTrials.gov
• Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial#640570ClinicalTrials.gov
• TFE3-rearranged and TFEB-altered renal cell carcinoma: from classification to real life. Insights from a national Italian survey#202799IRIS
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib#829067ClinicalTrials.gov
• Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma#899495ClinicalTrials.gov
• Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma#863056ClinicalTrials.gov
• Prospective Trial for Examining Hematuria Using Computed Tomography#850465ClinicalTrials.gov
• METABOLIC VULNERABILITIES IN CLEAR CELL RENAL CELL CARCINOMA#929383ScholarlyCommons
• Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma#907433ClinicalTrials.gov
• PET/MR Characterization of Renal Cell Carcinomas#909428ClinicalTrials.gov
• Clinicohistopathological characteristics of renal cell carcinoma in Jordan#5192Europe PMC
• Kidney Segmentation Dataset: Voxel-level Annotations for Renal Cell Carcinoma CT Imaging#124866DataCite
• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)#287526ClinicalTrials.gov
• Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)#800764ClinicalTrials.gov
• DC1s-CTL Cellular Therapy for Renal Cell Carcinoma#811358ClinicalTrials.gov
• Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma#866266ClinicalTrials.gov
• Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management#858089ClinicalTrials.gov
• Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma#878511ClinicalTrials.gov
• Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer#807509ClinicalTrials.gov
• Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma#872435ClinicalTrials.gov
• Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma#889420ClinicalTrials.gov
• Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma#902306ClinicalTrials.gov
• Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer#442090ClinicalTrials.gov
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors#825504ClinicalTrials.gov
• A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)#831984ClinicalTrials.gov